Detalles de la búsqueda
1.
Programmed cell death-1 receptor-mediated regulation of Tbet+NK1.1- innate lymphoid cells within the tumor microenvironment.
Proc Natl Acad Sci U S A
; 120(18): e2216587120, 2023 05 02.
Artículo
Inglés
| MEDLINE | ID: mdl-37098069
2.
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Br J Cancer
; 129(1): 38-45, 2023 07.
Artículo
Inglés
| MEDLINE | ID: mdl-37120671
3.
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
Br J Cancer
; 129(5): 811-818, 2023 09.
Artículo
Inglés
| MEDLINE | ID: mdl-37488446
4.
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
Oncologist
; 28(12): e1248-e1258, 2023 Dec 11.
Artículo
Inglés
| MEDLINE | ID: mdl-37260332
5.
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
N Engl J Med
; 383(12): 1139-1148, 2020 09 17.
Artículo
Inglés
| MEDLINE | ID: mdl-32877599
6.
Evolution of the Development of PARP Inhibitors.
Cancer Treat Res
; 186: 1-11, 2023.
Artículo
Inglés
| MEDLINE | ID: mdl-37978127
7.
Impact of an educational intervention for advanced cancer patients referred for early phase clinical trials.
Br J Nurs
; 32(15): 748-753, 2023 Aug 17.
Artículo
Inglés
| MEDLINE | ID: mdl-37596084
8.
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Int J Cancer
; 150(6): 993-1006, 2022 03 15.
Artículo
Inglés
| MEDLINE | ID: mdl-34724226
9.
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.
Cancer
; 128(17): 3185-3195, 2022 09 01.
Artículo
Inglés
| MEDLINE | ID: mdl-35737639
10.
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
Br J Cancer
; 127(1): 92-101, 2022 07.
Artículo
Inglés
| MEDLINE | ID: mdl-35568736
11.
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
Invest New Drugs
; 40(1): 91-98, 2022 02.
Artículo
Inglés
| MEDLINE | ID: mdl-34453241
12.
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Br J Cancer
; 125(4): 520-527, 2021 08.
Artículo
Inglés
| MEDLINE | ID: mdl-34040174
13.
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
Br J Cancer
; 125(4): 510-519, 2021 08.
Artículo
Inglés
| MEDLINE | ID: mdl-34040175
14.
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Br J Cancer
; 124(3): 574-580, 2021 02.
Artículo
Inglés
| MEDLINE | ID: mdl-33087895
15.
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
BMC Cancer
; 21(1): 761, 2021 Jul 01.
Artículo
Inglés
| MEDLINE | ID: mdl-34210290
16.
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
Br J Cancer
; 123(12): 1730-1736, 2020 12.
Artículo
Inglés
| MEDLINE | ID: mdl-32989226
17.
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor.
Br J Cancer
; 123(4): 525-533, 2020 08.
Artículo
Inglés
| MEDLINE | ID: mdl-32523090
18.
A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.
Br J Cancer
; 122(8): 1141-1145, 2020 04.
Artículo
Inglés
| MEDLINE | ID: mdl-32076124
19.
Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.
Br J Cancer
; 122(8): 1272, 2020 Apr.
Artículo
Inglés
| MEDLINE | ID: mdl-32203218
20.
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
Br J Cancer
; 123(9): 1360-1369, 2020 10.
Artículo
Inglés
| MEDLINE | ID: mdl-32741975